Evotec to start phase 2 study of EVT 201 in insomnia

By Lisa Kerner

Charlotte, N.C., Sept. 21 - Evotec AG began a multi-center, double-blind phase 2 clinical trial to evaluate the efficacy of EVT 201 in a three way cross-over design in 66 patients with primary insomnia.

Patients will be given two dose levels of EVT 201 and placebo in a random order for two consecutive nights. There will be 5 to 12 day washout between each period.

EVT 201 reduced wake after sleep onset and increased total sleep time and quality of sleep in previous trials, according to the Hamburg, Germany biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.